HER2-Negative Metastatic Breast Cancer Market Forecast 2036: Rising Demand, Novel Therapies, and Commercial Potential - DelveInsight

DelveInsight's "HER2-Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the HER2-Negative Metastatic Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the HER2-Negative Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Negative Metastatic Breast Cancer Market Forecast
https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the HER2-Negative Metastatic Breast Cancer Market Report:
• The HER2-Negative Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, Genentech Therapeutics' Phase III clinical trial of Itovebi achieved the key oncology benchmark of improved overall survival (OS) in patients with certain forms of metastatic breast cancer, while also delaying disease progression. Additional findings from the randomized, double-blind study (NCT04191499) revealed that Itovebi, also known as inavolisib, demonstrated a statistically significant and clinically meaningful improvement in OS when combined with Ibrance (palbociclib) and Faslodex (fulvestrant). This benefit was specifically observed in patients with PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-Negative Metastatic Breast Cancer.
• In January 2025, Mersana Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has granted an additional Fast Track designation to XMT-1660. This designation applies to the treatment of advanced or metastatic breast cancer in patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC), who have previously received a topoisomerase-1 inhibitor ADC.
• In November 2024, Pyxis Oncology, Inc. reported encouraging preliminary results from its ongoing Phase I dose-escalation study assessing PYX-201 across various solid tumor types.
• The US experienced 253,465 new instances of breast cancer in 2020, according to the Global Cancer Observatory (2020)
• According to data from Surveillance, Epidemiology and End Results (SEER, n.d.), the US female population experiences the diagnosis of more than 200,000 new instances of breast cancer each year
• According to the Global Cancer Observatory (2020), there were 69,697 new cases of breast cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively, in 2020
• Key HER2-Negative Metastatic Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
• Key HER2-Negative Metastatic Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
• The HER2-Negative Metastatic Breast Cancer epidemiology based on gender analyzed that HER2-Negative Metastatic Breast Cancer mainly develops in older women
• The HER2-Negative Metastatic Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Negative Metastatic Breast Cancer pipeline products will significantly revolutionize the HER2-Negative Metastatic Breast Cancer market dynamics.

HER2-Negative Metastatic Breast Cancer Overview
HER2-Negative Metastatic Breast Cancer is a type of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body (metastatic) and does not overexpress the human epidermal growth factor receptor 2 (HER2) protein. Since HER2 is not overactive, HER2-targeted therapies like trastuzumab are ineffective. Treatment typically focuses on hormonal therapy, chemotherapy, or immunotherapy, depending on hormone receptor status (HR-positive or triple-negative). HER2-negative status influences prognosis and treatment strategy.

Get a Free sample for the HER2-Negative Metastatic Breast Cancer Market Report
https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

HER2-Negative Metastatic Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

HER2-Negative Metastatic Breast Cancer Epidemiology Segmentation:
The HER2-Negative Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of HER2-Negative Metastatic Breast Cancer
• Prevalent Cases of HER2-Negative Metastatic Breast Cancer by severity
• Gender-specific Prevalence of HER2-Negative Metastatic Breast Cancer
• Diagnosed Cases of Episodic and Chronic HER2-Negative Metastatic Breast Cancer

Download the report to understand which factors are driving HER2-Negative Metastatic Breast Cancer epidemiology trends @ HER2-Negative Metastatic Breast Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

HER2-Negative Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Negative Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-Negative Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the HER2-Negative Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2-Negative Metastatic Breast Cancer Therapies and Key Companies
• Paclitaxel: Dana-Farber Cancer Institute
• Doxorubicin: Genentech, Inc.
• AZD9833: AstraZeneca
• Pembrolizumab: Merck Sharp & Dohme LLC
• TF2 - 68 Ga-IMP-288: Gilead Sciences
• BGB-290: BeiGene
• Eribulin: Eisai Inc.
• Dapagliflozin: Novartis Pharmaceuticals
• ADG106: Adagene Inc
• Famitinib Malate: Jiangsu HengRui Medicine Co., Ltd
• Talazoparib Tosylate: Pfizer
• Letrozole: Novartis
• CX-2009: CytomX Therapeutics
• SM-88: Tyme, Inc
• Neratinib: Puma Biotechnology, Inc.
• G1T38: G1 Therapeutics, Inc.
• Onapristone: Context Therapeutics Inc.

Discover more about therapies set to grab major HER2-Negative Metastatic Breast Cancer market share @ HER2-Negative Metastatic Breast Cancer Treatment Market
https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

HER2-Negative Metastatic Breast Cancer Market Drivers
• Rising Incidence of Breast Cancer: The increasing global prevalence of HER2-negative metastatic breast cancer is expanding the patient population requiring advanced treatment options.
• Advancements in Targeted Therapies: The development of CDK4/6 inhibitors, PARP inhibitors, antibody-drug conjugates (ADCs), PI3K inhibitors, and AKT inhibitors is improving clinical outcomes and driving market growth.
• Growing Adoption of Precision Medicine: Increased use of biomarker testing, genomic profiling, and companion diagnostics enables personalized treatment strategies and optimized therapy selection.
• Robust Clinical Pipeline: Numerous investigational therapies, including next-generation ADCs, immunotherapies, and novel targeted agents, are progressing through clinical development.
• Increasing Use of Combination Therapies: Combining endocrine therapy with targeted agents and immunotherapies is enhancing progression-free survival and expanding treatment options.

HER2-Negative Metastatic Breast Cancer Market Barriers
• Development of Drug Resistance: Acquired resistance to endocrine therapies, CDK4/6 inhibitors, and other targeted treatments remains a major clinical challenge.
• High Cost of Novel Therapies: Premium pricing of targeted therapies, antibody-drug conjugates, and immunotherapies may limit patient access and reimbursement.
• Disease Heterogeneity: Molecular diversity within HER2-negative breast cancer complicates treatment selection and clinical trial design.
• Limited Treatment Options After Progression: Patients who develop resistance to first- and second-line therapies often have fewer effective treatment alternatives.
• Adverse Effects of Long-Term Therapy: Toxicities associated with targeted therapies and chemotherapy can affect treatment adherence and quality of life.

Scope of the HER2-Negative Metastatic Breast Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key HER2-Negative Metastatic Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
• Key HER2-Negative Metastatic Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 - 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
• HER2-Negative Metastatic Breast Cancer Therapeutic Assessment: HER2-Negative Metastatic Breast Cancer current marketed and HER2-Negative Metastatic Breast Cancer emerging therapies
• HER2-Negative Metastatic Breast Cancer Market Dynamics: HER2-Negative Metastatic Breast Cancer market drivers and HER2-Negative Metastatic Breast Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• HER2-Negative Metastatic Breast Cancer Unmet Needs, KOL's views, Analyst's views, HER2-Negative Metastatic Breast Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.